Zelquistinel (GATE-251, formerly AGN-241751) is an orally active small-molecule NMDA receptor positive allosteric modulator which is under development for the treatment of major depressive disorder (MDD) by Syndeio Biosciences, and previously by Allergan. == Pharmacology == Zelquistinel acts through a unique binding site on the NMDA receptor, independent of the glycine site, to positively modulate receptor activity and enhance NMDAR-mediated synaptic plasticity.
Zelquistinel (GATE-251, formerly AGN-241751) is an orally active small-molecule NMDA receptor positive allosteric modulator which is under development for the treatment of major depressive disorder (MDD) by Syndeio Biosciences, and previously by Allergan. == Pharmacology == Zelquistinel acts through a unique binding site on the NMDA receptor, independent of the glycine site, to positively modulate receptor activity and enhance NMDAR-mediated synaptic plasticity.
Source: Wikipedia "Zelquistinel" · CC BY-SA 4.0
Share this article: X · Bluesky